Vancouver, British Columbia–(Newsfile Corp. – March 11, 2021) – NeonMind Biosciences Inc. (CSE: NEON) (OTC: NMDBF) (FSE: 6UF) (“NeonMind“) is pleased to announce that on March 10, 2021 NeonMind engaged Certara®, the global leader in model-informed drug development to provide strategic integrated drug development support for the investigation of NeonMind’s psilocybin based drug candidates for the…


Previous articleNova Mentis Upgrades U.S. Listing to the OTCQB Venture Market
Next articleAion Therapeutic Files 4 New Patent Applications (Including for the Treatment of Human Cancers)